expert roundtables

Importance of Disease-Related Symptoms in Patients With Myeloproliferative Neoplasms

by Rami Komrokji, MD; Ruben A. Mesa, MD, FACP; and Katherine Walsh, MD, FACP

Overview

Symptoms of advanced myeloproliferative neoplasms (MPN) negatively impact quality of life and include fatigue, night sweats, itching, bone/muscle pain, and early satiety. Symptom relief is a primary goal of treatment, and the evaluation of disease-related symptoms is a crucial aspect of the response assessment. Addressing disease-related symptoms in patients with advanced or progressive MPN may benefit physical functioning, independence, and quality of life.

Q: Why are disease-related symptoms so important in MPN?

Ruben A. Mesa, MD, FACP

Director, Mays Cancer Center at UT Health San Antonio MD Anderson
Mays Family Foundation Distinguished University Presidential Chair
San Antonio, TX

“Persistence or worsening of symptoms is a sign of treatment failure.”

Ruben A. Mesa, MD, FACP

The symptoms of MPN are an important biologic aspect of the disease, and they represent the significant burden that patients face. We believe that these symptoms are linked to inflammation and cytokine activity; in myelofibrosis in particular, symptoms may be prognostic of worse outcomes. A goal of therapy is to eradicate symptoms, and a key part of assessing the efficacy of therapy is determining its effect on symptoms. How much is the patient still suffering with the disease? Severe pruritus can be quite disturbing; in fact, some patients have even committed suicide because their pruritus was so intractable. Symptom assessment is an important aspect of evaluating the response to treatment. Persistence or worsening of symptoms is a sign of treatment failure. Do we need to change therapy, or should we alter the dose to achieve better symptom relief? Symptoms are an important biomarker of the underlying disease. Inadvertent weight loss and cachexia, for example, can be a sign of progressive disease and may share biologic underpinnings with the disease process. There is a misconception that simply asking patients how they are feeling is somehow an appropriate substitute for a more structured intake, and, unfortunately, it is not. Additionally, a more structured approach need not undermine a practice’s workflow or efficiency. We administer a simple, 10-point symptom questionnaire to patients in our waiting area. It serves as the springboard for organizing our discussions with patients, and it has been helpful at our institution.

Rami Komrokji, MD

Senior Member
Section Head, Leukemia & MDS
Vice Chair, Department of Malignant Hematology
Moffitt Cancer Center
Professor of Oncologic Sciences
University of South Florida
Tampa, FL

“I think that the constitutional symptoms are key, and those patients with advanced or progressive MPN are often quite symptomatic.”

Rami Komrokji, MD

Symptom burden is a significant issue for patients with MPN. Symptoms are also biologically linked with the disease, so they relate to outcomes. The constitutional symptoms of patients with MPN are risk factors for poor outcomes and drive the changes in an individual’s functional status, particularly in those with myelofibrosis. Symptoms such as fatigue and bone pain can be quite limiting to a patient’s function, and our risk models incorporate constitutional symptoms as indicators of worse outcomes. One of the challenges with some of these constitutional symptoms is evaluating them more objectively in a busy clinical practice. Another challenge arises when patients with myelofibrosis are precluded from potentially curative therapies such as allogeneic stem cell transplantation because of a very poor performance status; and yet, when you evaluate these patients, you find that it is all disease related. Part of the benefit of treatment with Janus kinase 2 inhibition, in addition to the survival advantage that was indirectly observed in the studies, is an improvement in functioning and performance status and fewer disease-related complications. These end points are in contrast to altering the natural history of the disease or reversing fibrosis. Thus, I think that the constitutional symptoms are key, and those patients with advanced or progressive MPN are often quite symptomatic.    

Katherine Walsh, MD, FACP

Associate Professor of Clinical Internal Medicine
Division of Hematology
The James Cancer Hospital and Solove Research Institute
The Ohio State University Comprehensive Cancer Center
Columbus, OH

“To some patients, coming to terms with their illness is as important as gaining control of their symptoms.

Katherine Walsh, MD, FACP

We need to remember that symptoms have the greatest impact on a patient’s daily life. When we tell our patients that they have a chronic disease with a particular expected prognosis, they are usually most concerned about how their symptoms and treatment side effects will interfere with their ability to enjoy time with their friends and family. To some patients, coming to terms with their illness is as important as gaining control of their symptoms. Our center, along with many other hematology-oncology centers, uses intake forms that cover many of the constitutional symptoms associated with MPN, such as fatigue, loss of appetite, and night sweats. They include general questions, and the forms are relevant to nearly all of our patients. There are different levels of symptom assessment, and some, such as the ones used in clinical trials, may be more robust than others. There are occasions when symptoms guide therapy more so than laboratory findings. That is, in many patients with MPN, we reach a point where the laboratory goals have been met but the patient has ongoing symptoms. At this time, we would consider changing the type of therapy (eg, switching from phlebotomy and hydroxyurea to ruxolitinib in a patient with polycythemia vera). Our goal in this case would be to gain control of the symptoms while maintaining the laboratory responses.

References

Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs [published correction appears in J Clin Oncol. 2012;30(36):4590]. J Clin Oncol. 2012;30(33):4098-4103.

Harrison CN, Koschmieder S, Foltz L, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol. 2017;96(10):1653-1665.

Mesa RA, Miller CB, Thyne M, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: findings from the MPN Landmark survey. Cancer. 2017;123(3):449-458.

Mesa R, Verstovsek S, Kiladjian JJ, et al. Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. Eur J Haematol. 2016;97(2):192-200.

More in Myeloproliferative Neoplasms

Thumb

Myeloproliferative Neoplasms

Traditional and Nontraditional Risk Factors in Patients With Myeloproliferative Neoplasms

Clinical Topic Updates by Rami Komrokji, MD

The risk of vascular complications in patients with myeloproliferative neoplasms (MPN) may be predicted by older age, history of thrombosis, and ot...READ MORE

Thumb

Myeloproliferative Neoplasms

Treatment Recommendations for Durable Count Control in Polycythemia Vera

Clinical Topic Updates by Ruben A. Mesa, MD, FACP

Durable count control in patients with polycythemia vera (PV) involves achieving a delicate balance between hematocrit, platelet, and leukocyte cou...READ MORE

Thumb

Myeloproliferative Neoplasms

Resistance or Intolerance to Hydroxyurea in Patients With Polycythemia Vera

Patient Care Perspectives by Ruben A. Mesa, MD, FACP

Many patients with polycythemia vera (PV) benefit from hydroxyurea therapy, but some develop resistance or intolerance, as manifested by the persis...READ MORE

More In Oncology

Non-Small Cell Lung Cancer

Biomarkers for Response to Immune Checkpoint Inhibition

Clinical Topic Updates
by Bruce E. Johnson, MD

Non-Small Cell Lung Cancer

Newer Targets and Therapies for Non–Small Cell Lung Cancer

Expert Roundtables
by Jeffrey Crawford, MD; Bruce E. Johnson, MD; and Gregory J. Riely, MD, PhD